Sofia Scevola
Overview
Explore the profile of Sofia Scevola including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
27
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bailon L, Molto J, Curran A, Cadinanos J, Carlos Lopez Bernaldo de Quiros J, de Los Santos I, et al.
Nat Commun
. 2025 Mar;
16(1):2146.
PMID: 40038256
Building on results from the AELIX-002 trial with HIVACAT T-cell immunogen (HTI)-based vaccines, the AELIX-003 (NCT04364035) trial tested the safety of the combination of ChAdOx1.HTI (C) and MVA.HTI (M), with...
2.
Rigo-Bonnin R, Garcia-Tejada L, Mas-Bosch V, Imaz A, Tiraboschi J, Scevola S, et al.
Clin Chim Acta
. 2023 Dec;
552:117678.
PMID: 38042460
Background: Fixed-dose combinations of antiretroviral drugs are commonly used to treat HIV infection and therapeutic monitoring is not part of routine clinical practice. However, drug concentrations monitoring might have role...
3.
Scevola S, Niubo J, Domingo P, Verdejo G, Curran A, Diaz-Brito V, et al.
J Infect Dis
. 2023 Aug;
228(7):919-925.
PMID: 37526315
Background: Decay of HIV in seminal plasma (SP) and rectal fluid (RF) has not yet been described for the antiretroviral combination of dolutegravir (DTG) + lamivudine (3TC). Methods: In this...
4.
Donadeu L, Tiraboschi J, Scevola S, Torija A, Meneghini M, Jouve T, et al.
AIDS
. 2022 Jun;
36(10):1373-1382.
PMID: 35730384
Objective: While the course of natural immunization specific to SARS-CoV-2 has been described among convalescent coronavirus disease 2019 (COVID-19) people without HIV (PWOH), a thorough evaluation of long-term serological and...
5.
Tiraboschi J, Prieto P, Saumoy M, Silva A, Imaz A, Scevola S, et al.
Curr HIV Res
. 2022 Jun;
20(3):251-254.
PMID: 35676852
Background: We report NP, clinical and laboratory changes in patients switching from EVG/Cobi/FTC/TAF to BIC/FTC/TAF in clinical practice. Methods: A group of subjects switching from EVG/Cobi/FTC/TAF to BIC/F/TAF was prospectively...
6.
Scevola S, Imaz A, Cottrell M, Niubo J, Van Horne B, Tiraboschi J, et al.
Clin Infect Dis
. 2022 May;
75(11):2012-2015.
PMID: 35616112
Doravirine (DOR) concentrations and HIV-1 RNA were evaluated in genital fluids from adults with HIV on stable therapy who switched to DOR + FTC/TAF. High protein-unbound DOR concentrations were observed...
7.
Tiraboschi J, Scevola S, Dilly Penchala S, Challenger E, Else L, Prieto P, et al.
Clin Infect Dis
. 2021 Sep;
74(10):1855-1858.
PMID: 34549268
We determined total and unbound concentrations of doravirine (DOR) in cerebrospinal fluid and blood plasma. Total and unbound DOR concentrations in cerebrospinal fluid exceeded the half-maximal effective concentration against wild-type...
8.
Imaz A, Tiraboschi J, Niubo J, Martinez-Picado J, Cottrell M, Domingo P, et al.
Clin Infect Dis
. 2020 Sep;
73(7):e1991-e1999.
PMID: 32945851
Background: The pharmacokinetics of bictegravir (BIC) and its association with the decay of human immunodeficiency virus (HIV)-1 RNA in genital fluids and the rectum have not yet been addressed. Methods:...
9.
Scevola S, Tiraboschi J, Podzamczer D
Expert Opin Drug Saf
. 2020 May;
19(6):683-694.
PMID: 32356477
Introduction: Since the administration of the first integrase strand transfer inhibitor (INSTI) in 2007, most international treatment guidelines consider INSTI-based regimens to be the preferred antiretroviral combinations for HIV-1-infected patients...
10.
Rigo-Bonnin R, Tiraboschi J, Alvarez-Alvarez M, Perez-Fernandez G, Sanjuas-Iglesias M, Scevola S, et al.
J Pharm Biomed Anal
. 2020 Mar;
185:113250.
PMID: 32199329
Bictegravir is a novel integrase strand transfer inhibitor, administrated in co-formulation with tenofovir alafenamide and emtricitabine (Biktarvy®), indicated in the management of HIV-1 infection in patients not previously treated with...